Literature DB >> 25053470

Group sequential tests for long-term survival comparisons.

Brent R Logan1, Shuyuan Mo.   

Abstract

Sometimes in clinical trials, the hazard rates are anticipated to be nonproportional, resulting in potentially crossing survival curves. In these cases, researchers are usually interested in which treatment has better long-term survival. The log-rank test and the weighted log-rank test may not be appropriate or efficient to use here, because they are sensitive to differences in survival at any time and don't just focus on long-term outcomes. Also in a prospective clinical trial, patients are entered sequentially over calendar time, so that group sequential designs may be considered for ethical, administrative and economic concerns. Here we develop group sequential methods for testing the null hypothesis that the survival curves are identical after a prespecified time point. Several classes of tests are considered, including an integrated difference in survival probabilities after this time point, and linear or quadratic combinations of two component test statistics (pointwise comparisons of survival at the time point and comparisons of hazard rates after the time point). We examine the type I errors, stopping probabilities, and powers of these tests through simulation studies under the null and different alternatives, and we apply them to a real bone marrow transplant clinical trial.

Entities:  

Mesh:

Year:  2014        PMID: 25053470      PMCID: PMC4305035          DOI: 10.1007/s10985-014-9298-4

Source DB:  PubMed          Journal:  Lifetime Data Anal        ISSN: 1380-7870            Impact factor:   1.588


  8 in total

1.  A group sequential test for survival trials: an alternative to rank-based procedures.

Authors:  Z Li
Journal:  Biometrics       Date:  1999-03       Impact factor: 2.571

2.  Sequential methods for comparing years of life saved in the two-sample censored data problem.

Authors:  S Murray; A A Tsiatis
Journal:  Biometrics       Date:  1999-12       Impact factor: 2.571

3.  Group sequential designs for monitoring survival probabilities.

Authors:  D Y Lin; L Shen; Z Ying; N E Breslow
Journal:  Biometrics       Date:  1996-09       Impact factor: 2.571

4.  A partially grouped logrank test.

Authors:  R Sposto; D Stablein; S Carter-Campbell
Journal:  Stat Med       Date:  1997-03-30       Impact factor: 2.373

5.  Weighted Kaplan-Meier statistics: a class of distance tests for censored survival data.

Authors:  M S Pepe; T R Fleming
Journal:  Biometrics       Date:  1989-06       Impact factor: 2.571

6.  Group sequential methods for comparison of cure rates in clinical trials.

Authors:  J W Lee; H N Sather
Journal:  Biometrics       Date:  1995-06       Impact factor: 2.571

7.  In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993).

Authors:  Anthony H Goldstone; Susan M Richards; Hillard M Lazarus; Martin S Tallman; Georgina Buck; Adele K Fielding; Alan K Burnett; Raj Chopra; Peter H Wiernik; Letizia Foroni; Elisabeth Paietta; Mark R Litzow; David I Marks; Jill Durrant; Andrew McMillan; Ian M Franklin; Selina Luger; Niculae Ciobanu; Jacob M Rowe
Journal:  Blood       Date:  2007-11-29       Impact factor: 22.113

8.  Comparing treatments in the presence of crossing survival curves: an application to bone marrow transplantation.

Authors:  Brent R Logan; John P Klein; Mei-Jie Zhang
Journal:  Biometrics       Date:  2008-01-11       Impact factor: 1.701

  8 in total
  1 in total

1.  Delayed treatment effects, treatment switching and heterogeneous patient populations: How to design and analyze RCTs in oncology.

Authors:  Robin Ristl; Nicolás M Ballarini; Heiko Götte; Armin Schüler; Martin Posch; Franz König
Journal:  Pharm Stat       Date:  2020-08-23       Impact factor: 1.894

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.